Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Notable: Simple-Prep Controlled Embolic Results posted: Nov 19, 2026
- Notable: Nutrition and Swelling Primary endpoint(s) modified
- Notable: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept · Newly Diagnosed Pulmonary Arterial Hypertension Primary endpoint(s) modified
- Notable: Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy · Advanced Non-small Cell Lung Cancer Primary completion pushed from Aug 31, 2025 to Oct 31, 2028
- Notable: Vinpocetine in Healthy Volunteers Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026
- Notable: Talazoparib + Tazemetostat for mCRPC Results posted: Nov 19, 2026
- Notable: Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent Enrollment increased: 2600 → 4464 participants
- Notable: Automated, Assistive, Non-Contact Sleep Quality Monitor for Older Adults Recruitment opened
- Notable: BFR and Neuromuscular Training in Knee Osteoarthritis (KOA) Primary endpoint(s) modified
- Notable: Screen Time Exposure and Behavioral Outcomes Primary endpoint(s) modified
- Notable: Cost-Effectiveness of the Healthy Beat Acupunch Regimen in Community-Dwelling Older Adults Primary endpoint(s) modified
- Notable: Perianchor Cyst Formation, Tendon Healing, and Clinical Outcomes Following Arthroscopic Rotator Cuff Repair Primary endpoint(s) modified
- Notable: Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache) Recruitment opened
- Notable: Empowered Relief for Caregivers Recruitment opened
- Notable: SHOFU FX-LC RMGI Restoration Versus FUJI II RGMI · Anterior Carious Cervical Lesions Enrollment increased: 36 → 56 participants
- Notable: Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified
- Notable: Validation of AR Based Neuronavigation System Recruitment opened
- Notable: Paclitaxel Polymeric Micelles for Injection · Metastatic Breast Cancer Primary completion pushed from Dec 2025 to Dec 31, 2027
- Notable: Pacritinib · VEXAS Syndrome (PAXIS) Primary completion pushed from Dec 30, 2026 to Oct 30, 2028
- Notable: REC-1245 · Unresectable, Locally Advanced, or Metastatic Cancer Primary and study completion pushed from Oct 30, 2028 to Jul 2029
- Notable: SNH-119014 · Non-transfusion-dependent Thalassemia (NTDT) Primary completion pushed from Mar 29, 2027 to Sep 30, 2027
- Notable: Abemaciclib and Elacestrant · Brain Metastasis Due to ER+/HER-2- Breast Cancer Primary completion pushed from Dec 2026 to Aug 2027
- Notable: Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old Primary completion pushed from Jun 2026 to Jun 2027
- Notable: (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study Primary completion pushed from Aug 2026 to Aug 2027
- Notable: Efficiency of Cytoflavin, · Ischemic Stroke Not Receiving Reperfusion Therapy Primary completion pushed from Sep 30, 2025 to Jun 1, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates